$16.790
-1.093 (-6.51%)At close
TRVI News
TRVI Events
Trevi Therapeutics Initiates Phase 3 Trial of Haduvio
"We are on track with our clinical trial plans as we initiated our first Phase 3 trial of Haduvio in patients with IPF-related chronic cough and a Phase 2b trial in patients with RCC during the second quarter. We expect to initiate our second Phase 3 trial in IPF-related chronic cough during the third quarter and meet with the FDA regarding our planned non-IPF ILD-related chronic cough trial," said Jennifer Good, President and CEO of Trevi Therapeutics. "With an experienced team dedicated to advancing our trials across all three of our chronic cough indications, and a strong balance sheet following our April financing, we are well positioned to execute on our plans. We recognize the significant unmet need these patients have and are working diligently to enroll our trials. Following the recent changes in the competitive landscape, and with no FDA-approved therapies currently available, Haduvio has the potential to become a first-in-class therapy that makes a meaningful difference in patients' lives."
Serina Therapeutics Appoints Farrell Simon to Board of Directors
Serina Therapeutics (SER) announced the appointment of Farrell Simon to its board of directors, effective immediately. Simon will also serve on the board's audit and compensation committees. He currently serves as chief commercial officer, or COO, at Trevi Therapeutics (TRVI), where he leads commercial strategy, lifecycle management, and pre-commercial readiness planning.
Trevi Therapeutics Stock Rises 10.9% to $19.25
Trevi Therapeutics is up 10.9%, or $1.89 to $19.25.
Trevi Therapeutics Stock Rises 10.4% to $19.16
Trevi Therapeutics is up 10.4%, or $1.80 to $19.16.
Trevi Therapeutics Initiates Multiple Clinical Trials
"We are entering an important phase of execution for Trevi, with study initiations anticipated across our chronic cough programs," said Jennifer Good, President and CEO of Trevi Therapeutics. "Following a very productive End-of-Phase 2 meeting with the FDA on our lead program in IPF-related chronic cough, we are excited to initiate multiple clinical trials this quarter, including our first Phase 3 in IPF-related chronic cough and our Phase 2b in RCC. With an expected cash runway into 2030, we are well-positioned to execute on our development strategy and advance towards a potential FDA submission in IPF-related chronic cough. We believe successful execution of our strategy would establish Trevi as the leader in providing best-in-class therapy in chronic cough indications with significant unmet needs and no FDA-approved therapies."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.